Tegafur,Gimeracil and Oteracil Potassium
- Generic Name
- Tegafur,Gimeracil and Oteracil Potassium
- Brand Names
- -
- Drug Type
- -
- Chemical Formula
- -
- CAS Number
- -
- Unique Ingredient Identifier
- -
- Indication
用于不能切除的局部晚期或转移性胃癌。
用于治疗成人胆道癌【日本PMDA已批准；《胆管癌诊断与治疗-外科专家共识》】。
- Associated Conditions
- -
- Associated Therapies
- -
A Feasibility Study of Oral Adjuvant Chemotherapy With S-1
- First Posted Date
- 2011-10-25
- Last Posted Date
- 2014-09-25
- Lead Sponsor
- Tomoshi Tsuchiya
- Target Recruit Count
- 55
- Registration Number
- NCT01459185
- Locations
- 🇯🇵
Division of Surgical Oncology, Nagasaki University Graduate School of BIomedical Sciences, Nagasaki, Japan
S-1 Versus S-1 Plus Cisplatin as an Adjuvant Chemotherapy to Treat Gastric Cancer
- First Posted Date
- 2011-08-31
- Last Posted Date
- 2012-01-05
- Lead Sponsor
- Kyungpook National University Hospital
- Target Recruit Count
- 218
- Registration Number
- NCT01426646
- Locations
- 🇰🇷
Ulsan University Hospital, Ulsan, Korea, Republic of
🇰🇷Donga university hospital, Busan, Korea, Republic of
Cetuximab in Combination With S-1 and Cisplatin in Gastric Cancer
- First Posted Date
- 2011-07-07
- Last Posted Date
- 2013-11-20
- Lead Sponsor
- Merck KGaA, Darmstadt, Germany
- Target Recruit Count
- 40
- Registration Number
- NCT01388790
- Locations
- 🇩🇪
Please contact the Merck KGaA Communication Center located in, Darmstadt, Germany
Phase I Study of Gemcitabine or S-1 Adjuvant Therapy After Hemihepatectomy for Biliary Tract Cancer
- First Posted Date
- 2011-02-08
- Last Posted Date
- 2014-10-23
- Lead Sponsor
- Kansai Hepatobiliary Oncology Group
- Target Recruit Count
- 6
- Registration Number
- NCT01291615
- Locations
- 🇯🇵
Osaka University, Graduate School of Medicine, Osaka, Japan
A Phase I Study of S-1 in Combination With Radiotherapy in Locally Advanced or Recurrent Gastric Cancer
- First Posted Date
- 2011-02-08
- Last Posted Date
- 2013-09-18
- Lead Sponsor
- Chinese Academy of Medical Sciences
- Target Recruit Count
- 27
- Registration Number
- NCT01291407
- Locations
- 🇨🇳
Department of Radiation Oncology, Cancer Hospital, Chinese Academy of Medical Sciences (CAMS) and Peking Union Medical College (PUMC), Beijing, China
Preoperative S-1/OHP With Radiation Therapy for Low-lying Rectal Carcinoma in Neo-adjuvant Setting
- First Posted Date
- 2010-10-25
- Last Posted Date
- 2012-11-27
- Lead Sponsor
- Japan Clinical Cancer Research Organization
- Target Recruit Count
- 45
- Registration Number
- NCT01227239
- Locations
- 🇯🇵
Nagoya University Graduate School of Medicine, Nagoya, Japan
🇯🇵Osaka Medical College, Osaka, Japan
🇯🇵Tokyo University, Tokyo, Japan
S-1 and Radiotherapy in Elderly Patients With Esophageal Cancer
- First Posted Date
- 2010-08-04
- Last Posted Date
- 2012-03-06
- Lead Sponsor
- Zhejiang Cancer Hospital
- Target Recruit Count
- 12
- Registration Number
- NCT01175447
- Locations
- 🇨🇳
Zhejiang Cancer Hospital, Hangzhou, Zhejiang, China
Sorafenib Plus S-1 in Advanced Solid Tumors
- First Posted Date
- 2010-05-24
- Last Posted Date
- 2015-10-19
- Lead Sponsor
- National Health Research Institutes, Taiwan
- Target Recruit Count
- 30
- Registration Number
- NCT01128998
- Locations
- 🇨🇳
National Cheng-Kung University Hospital, Tainan City, Taiwan
Study of S-1 as Second Line Treatment on Advanced Pancreatic Cancers
- First Posted Date
- 2010-02-24
- Last Posted Date
- 2014-01-16
- Target Recruit Count
- 92
- Registration Number
- NCT01074996
- Locations
- 🇨🇳
307 Hospital of PLA, Beijing, Beijing, China
Study of Cediranib Plus Cisplatin Plus Capecitabine/S-1 in Japanese Gastric Cancer Patients
- Conditions
- Interventions
- First Posted Date
- 2009-08-17
- Last Posted Date
- 2011-06-14
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 14
- Registration Number
- NCT00960349
- Locations
- 🇯🇵
Research Site, Chuo, Tokyo, Japan
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.